fludeoxyglucose f-18 injection, solution
the university of texas southwestern medical center - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f 18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
fludeoxyglucose f 18 injection, solution
pharmalogic puerto rico, inc. - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d
fludeoxyglucose (18f) iba solution for injection
jv healthcare limited - fludeoxyglucose 185 mbq/ml - solution for injection
18f-fludeoxyglucose (18f-fdg) solution
isologic innovative radiopharmaceuticals ltd. - fludeoxyglucose 18f - solution - 7400mbq - fludeoxyglucose 18f 7400mbq - roentgenography
fludeoxyglucose f18 injection
the feinstein institute for medical research - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 300 mci in 1 ml - for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none. pregnancy category c animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. consider alternative diagnostic tests in a pregnant woman; administer fludeoxyglucose f 18 injection only if clearly needed. it is not known whether fludeoxyglucose f 18 injection is excreted in human milk. consider alternative diagnostic tests in women who are breast-feeding. use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if fludeoxyglucose f 18 injection is administered to a woman who is breast-feeding. the safety and effectiveness of fludeoxyglucose f 18 injection in pediatric patients with epilepsy is established on the basis of studies in adult and
fludeoxyglucose f-18- fludeoxyglucose f-18 injection injection
university of north dakota - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - fludeoxyglucose f 18 injection,usp is indicated in pet (positron emission tomography) for: 1. identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. fludeoxyglucose f 18 injection, usp is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. none known
efdege 1 gbq/ml inj. sol. i.v. vial
iason labormedizin gmbh & co. kg - fludeoxyglucose (18 f) 1 gbq/ml - solution for injection - 1 gbq/ml - fludeoxyglucose (f-18) - fludeoxyglucose (18f)
glucogast 1 850 mbq/ml inj. sol. i.v. vial
uz leuven - fludeoxyglucose (18 f) 1850 mbq/ml - solution for injection - 1850 mbq/ml - fludeoxyglucose (f-18) 1850 mbq/ml - fludeoxyglucose (18f)
glucotrace 185 mbq/ml inj. sol. i.v. vial
nucleis sa-nv - fludeoxyglucose (18 f) 185 mbq/ml - solution for injection - 185 mbq/ml - fludeoxyglucose (f-18) 185 mbq/ml - fludeoxyglucose (18f)
gluscan 600 mbq/ml inj. sol. i.v. vial
advanced accelerator applications - fludeoxyglucose (18 f) 600 mbq/ml - solution for injection - 600 mbq/ml - fludeoxyglucose (f-18) 600 mbq/ml - fludeoxyglucose (18f)